OJ
OJU1.F Oramed Pharmaceuticals Inc
- Market cap
- EUR 150M
- P/E
- 1.0x
- P/B
- 0.52x
- ROE
- 53.1%
- Dividend yield
- 5.99%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is OJU1.F undervalued?
Graham numberThe Graham number of Oramed Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oramed Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Oramed Pharmaceuticals Inc yet.
Oramed Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquarter…
Full company profileOramed Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oramed Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 2.46M | 2.45M | 2.70M | 2.71M | 2.70M | 2.70M | 1.34M | 0.00 | 2.00M | 0.00 |
| Gross Profit | - | 2.27M | 2.54M | 2.61M | 2.71M | 2.70M | - | - | 0.00 | 13.0K | 0.00 |
| Operating Income | - | -10.8M | -13.5M | -14.6M | -11.8M | -24.2M | -40.6M | -15.8M | -12.8M | -15.1M | -16.1M |
| EBITDA | - | -10.8M | -13.5M | -14.6M | -11.8M | -24.1M | -37.6M | 7.32M | -14.9M | 75.4M | 4.62M |
| Net Income | - | -10.5M | -12.7M | -14.4M | -11.5M | -22.2M | -36.6M | 5.53M | -19.1M | 64.1M | 169M |
| EPS | - | -0.77 | -0.73 | -0.83 | -0.49 | -0.63 | -0.92 | 0.14 | -0.48 | 1.63 | 4.08 |
| Balance Sheet | |||||||||||
| Total Assets | - | 38.7M | 47.4M | 34.7M | 44.6M | 128M | 162M | 221M | 155M | 231M | 370M |
| Total Liabilities | - | 19.5M | 16.3M | 15.3M | 11.8M | 11.5M | 10.5M | 57.7M | 9.93M | 31.1M | 52.2M |
| Shareholders' Equity | - | 19.2M | 31.1M | 19.4M | 32.9M | 116M | 152M | 164M | 146M | 200M | 317M |
| Cash & Short-term Investments | - | 3.97M | 5.00M | 3.33M | 19.3M | 77.2M | 40.5M | 9.06M | 54.4M | 45.9M | 15.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.66M | -5.83M | -14.7M | -12.9M | -24.8M | -21.2M | -27.9M | -10.3M | -8.41M | -9.15M | -4.77M |
| Capital Expenditure | 0.00 | 7.00K | 5.00K | 15.0K | 960K | 375K | 496K | 254K | 18.0K | 1.93M | 9.33K |
| Free Cash Flow | - | -5.84M | -14.7M | -13.0M | -12.5M | -21.6M | -28.4M | -10.5M | -8.43M | -11.1M | -4.51M |
| Ratios | |||||||||||
| ROE | - | -54.5% | -40.9% | -74.0% | -35.0% | -19.2% | -24.1% | 3.4% | -13.0% | 32.1% | 53.1% |
| ROA | - | -27.1% | -26.9% | -41.4% | -25.8% | -17.4% | -22.6% | 2.5% | -12.3% | 27.7% | 45.6% |
| Net Profit Margin | - | -426.7% | -519.7% | -531.1% | -424.8% | -822.7% | -1,352.6% | 412.3% | - | 3,202.5% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Oramed Pharmaceuticals Inc dividends
- Dividend yield
- 5.99%
- Forward dividend
- 0.21 EUR
- Payout ratio
- -
- Ex-dividend date
- Jan 16, 2026
Last stock split: 1:12 on Jan 23, 2013.
Who owns Oramed Pharmaceuticals Inc
- Insiders 21.27%
- Institutions 45.69%
- Public & others 33.04%
- Shares outstanding 41.6M
- Free float 29.8M
Oramed Pharmaceuticals Inc company profile
- Company name
- Oramed Pharmaceuticals Inc
- Ticker
- OJU1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- August
- Address
- 1185 Avenue of the Americas, New York, NY, United States, 10036
- Phone
- 844 967 2633
- Website
- oramed.com
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Oramed Pharmaceuticals Inc management
4- Mr. Nadav Kidron Esq.President, CEO & Executive Chairman · born 1974
- Mr. Joshua HexterChief Operating & Business Officer · born 1970
- Dr. Miriam Kidron Ph.D.Chief Scientific Officer & Director · born 1940
- Mr. Avraham GabayCFO, Treasurer & Secretary · born 1985